MX2016003979A - Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica. - Google Patents

Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.

Info

Publication number
MX2016003979A
MX2016003979A MX2016003979A MX2016003979A MX2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
lupus erythematosus
systemic lupus
nephritis
Prior art date
Application number
MX2016003979A
Other languages
English (en)
Inventor
Toru Kawamura
Yasushi Fujitani
Masayuki Takizawa
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX2016003979A publication Critical patent/MX2016003979A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención brinda un método para profilaxis o el tratamiento de lupus eritematoso sistémico y/o nefritis lúpica en un paciente que lo necesita, que comprende administrarle una cantidad eficaz de ácido [(1R)-1-({[(2,5-diclorobenzoil)amino]acet il}amino)-3-metilbutil]borónico o un éster de ácido cítrico de éste o una sal farmacéuticamente aceptable de estos a un paciente.
MX2016003979A 2013-10-03 2014-10-02 Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica. MX2016003979A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361886403P 2013-10-03 2013-10-03
PCT/US2014/058738 WO2015051067A1 (en) 2013-10-03 2014-10-02 Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis

Publications (1)

Publication Number Publication Date
MX2016003979A true MX2016003979A (es) 2016-06-15

Family

ID=51842818

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003979A MX2016003979A (es) 2013-10-03 2014-10-02 Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.

Country Status (10)

Country Link
US (2) US20160250238A1 (es)
EP (1) EP3052105A1 (es)
JP (1) JP2016531886A (es)
KR (1) KR20160058886A (es)
CN (1) CN105705149A (es)
BR (1) BR112016007237A2 (es)
CA (1) CA2925935A1 (es)
EA (1) EA201690686A1 (es)
MX (1) MX2016003979A (es)
WO (1) WO2015051067A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3813817A4 (en) * 2018-06-27 2022-08-10 Algernon Pharmaceuticals Inc. USE OF ACTARIT IN THE PROPHYLAXIS OR TREATMENT OF KIDNEY FIBROSIS OR KIDNEY DISEASE
WO2021225397A1 (ko) * 2020-05-07 2021-11-11 (주)뉴로라이브 우울증 치료를 위한 사이클로세린 및 펜톡시필린 병용 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU2002243646B2 (en) 2001-01-25 2006-06-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009020448A1 (en) * 2007-08-06 2009-02-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
MX349769B (es) * 2008-06-17 2017-08-11 Millennium Pharm Inc Compuestos de éster boronato y composiciones farmacéuticas de los mismos.
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
EA029521B1 (ru) 2010-03-31 2018-04-30 Милленниум Фармасьютикалз, Инк. Производные 1-амино-2-циклопропилэтилбороновой кислоты
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
US20140121182A1 (en) * 2011-06-22 2014-05-01 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use

Also Published As

Publication number Publication date
WO2015051067A1 (en) 2015-04-09
KR20160058886A (ko) 2016-05-25
BR112016007237A2 (pt) 2017-09-12
US20180099000A1 (en) 2018-04-12
EP3052105A1 (en) 2016-08-10
CN105705149A (zh) 2016-06-22
CA2925935A1 (en) 2015-04-09
JP2016531886A (ja) 2016-10-13
US20160250238A1 (en) 2016-09-01
EA201690686A1 (ru) 2016-08-31

Similar Documents

Publication Publication Date Title
PH12020500286A1 (en) Use of agonists of formly peptide receptor 2 for treating ocular inflammatory diseases
PH12016500649A1 (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs
ZA201602777B (en) Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
MX2016007067A (es) Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia.
PH12016501122A1 (en) Delayed release compositions of linaclotide
NZ702967A (en) Diclofenac formulations
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
IN2015DN01023A (es)
MX2016003979A (es) Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
MX2015007862A (es) Derivado de amida del acido cinamico.
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
IN2013MU03428A (es)
MX2016002139A (es) Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.
MX366118B (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
UA87249U (ru) Гель для лечения ран во второй фазе раневого процесса
IN2014DE00822A (es)
MD4291B1 (ro) Preparat medicamentos pentru tratamentul otitelor